Recommendations for screening and prevention of tuberculosis in patients with HIV and for screening for HIV in patients with tuberculosis and their contacts.

© 2003 Canadian Medical Association or its licensors The HIV epidemic has had a dramatic impact on rates of tuberculosis (TB) and on TB control in populations where both infections are prevalent. HIV infection, in particular advanced HIV infection (AIDS), is more potent than any other risk factor for the progression to disease of recent or remotely acquired TB infection. It destroys or renders ineffectual the 2 immune cells most important to the containment of tubercle bacilli, macrophages and CD4 receptor bearing lymphocytes. Among people coinfected with Mycobacterium tuberculosis and HIV before availability of highly active antiretroviral therapy, the estimated risk of active TB relative to patients with no other known risk factor for active TB was 170.0 times greater for AIDS and 113.0 times greater for HIV infection without AIDS. Cases of reactivation TB attributable to HIV infection increase the risk of transmission of M. tuberculosis within the community, thereby constituting a second, indirect mechanism by which HIV increases TB morbidity. In Canada, dormant or latent TB infection is most common in 4 groups: foreign-born people from countries where TB is endemic, Aboriginals, the inner-city poor and homeless, and elderly people. Coinfection with HIV is common among inner-city people with a history of injection drug use, and recent data suggest that HIV/AIDS is increasing among Aboriginals and among foreign-born people from countries where TB is endemic. Treatment of latent TB infection reduces the risk of progression to active disease in people with HIV–TB coinfection. Patients with TB constitute an important “sentinel” population for HIV screening. In some African countries with high TB prevalence, the prevalence of HIV among TB patients exceeds 70%. In the United States, between 1985 and 1992, TB patients were 204–fold more likely to have AIDS than the general population. The benefits of identifying previously unrecognized HIV infection are substantial, in terms of both preventing future HIV transmission and providing antiretroviral therapy to affected patients. Knowledge of the HIV serostatus of TB patients may also influence the treatment of their TB. Even among those not receiving antiretroviral therapy there may be an increased risk of adverse reactions from anti-TB drugs. Because HIV-infected patients are at risk of peripheral neuropathy, coadministration of pyridoxine with isoniazid may be prudent. Some HIV-infected TB patients have reportedly experienced malabsorption of their anti-TB drugs, so measurement of serum drug levels Recommendations for screening and prevention of tuberculosis in patients with HIV and for screening for HIV in patients with tuberculosis and their contacts